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ABSTRACT
Background: Recurrent 15q13.3 microdeletions were
recently identified with identical proximal (BP4) and distal
(BP5) breakpoints and associated with mild to moderate
mental retardation and epilepsy.
Methods: To assess further the clinical implications of this
novel 15q13.3 microdeletion syndrome, 18 new probands
with a deletion were molecularly and clinically charac-
terised. In addition, we evaluated the characteristics of a
family with a more proximal deletion between BP3 and BP4.
Finally, four patients with a duplication in the BP3–BP4–BP5
region were included in this study to ascertain the clinical
significance of duplications in this region.
Results: The 15q13.3 microdeletion in our series was
associated with a highly variable intra- and inter-familial
phenotype. At least 11 of the 18 deletions identified were
inherited. Moreover, 7 of 10 siblings from four different
families also had this deletion: one had a mild
developmental delay, four had only learning problems
during childhood, but functioned well in daily life as adults,
whereas the other two had no learning problems at all. In
contrast to previous findings, seizures were not a
common feature in our series (only 2 of 17 living
probands). Three patients with deletions had cardiac
defects and deletion of the KLF13 gene, located in the
critical region, may contribute to these abnormalities. The
limited data from the single family with the more proximal
BP3–BP4 deletion suggest this deletion may have little
clinical significance. Patients with duplications of the
BP3–BP4–BP5 region did not share a recognisable
phenotype, but psychiatric disease was noted in 2 of 4
patients.
Conclusions: Overall, our findings broaden the pheno-
typic spectrum associated with 15q13.3 deletions and
suggest that, in some individuals, deletion of 15q13.3 is
not sufficient to cause disease. The existence of
microdeletion syndromes, associated with an unpredict-
able and variable phenotypic outcome, will pose the
clinician with diagnostic difficulties and challenge the
commonly used paradigm in the diagnostic setting that
aberrations inherited from a phenotypically normal parent
are usually without clinical consequences.
The increased resolution of molecular karyotyping
has led to the delineation of several new submicro-
scopic deletion and duplication syndromes.1–4 The
occurrence of these genomic disorders5 is often
mediated by low copy repeats (LCRs) which can
give rise to various genomic changes by non-allelic
homologous recombination (NAHR).6 Recently,
Sharp et al reported a novel microdeletion syn-
drome caused by recurrent deletions of 15q13.3
mediated by NAHR.7 The estimated frequency of
this syndrome among mentally retarded patients is
0.29%, which is comparable with the frequencies of
Prader–Willi syndrome (PWS), Angelman syn-
drome (AS), and Williams–Beuren syndrome.7
The proximal 15q region is characterised by a
high density of segmentally duplicated blocks8–10
and therefore prone to several genomic rearrange-
ments leading to partial aneuploidy. The break-
points (BPs) of such rearrangements cluster in the
segmentally duplicated blocks, suggesting NAHR
as the mechanism of rearrangement.11 So far, six
BPs have been characterised in the chromosome
15q11q14 region.12 Deletions between BP1–BP3 and
BP2–BP3 give rise to the clinically well known
syndromes of PWS and AS caused by lack of
expression of imprinted genes between BP2 and
BP3.13 Duplications of the PW/AS region (BP1–
BP3), either as a result of an interstitial duplication
or due to a supernumerary derivative chromosome,
are associated with learning disabilities, autistic
behaviour and seizures.14 15 In addition, larger
deletions and duplications, including the PWS/AS
region, extending to BP4 and BP5, have been
described and result in a more extensive phenotype
than the original described syndromes.16–18 A more
distal microdeletion comprising BP5 and BP6 was
described in a mentally retarded patient with cleft
palate and an atrial ventricular septal defect.19
Sharp et al were the first to describe interstitial
deletions and a duplication, comprising the BP4–
BP5 region only, leading to a novel microdeletion
syndrome on 15q13.3.7 Rearrangements in this
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region arise when the flanking duplicons are positioned in a
direct orientation, most probably through an inversion poly-
morphism of the BP4–BP5 region, which generates a configura-
tion predisposing to NAHR.10 20 In total, six patients with a
BP4–BP5 deletion and three patients with a BP3–BP5 deletion
were reported. These patients showed mild to moderate mental
retardation and seven of the nine deletion cases had epilepsy
and/or electroencephalogram (EEG) abnormalities. Although
various dysmorphisms were noted among the patients, there
was no consistent or recognisable phenotype. More recently,
two studies concerning microdeletions associated with schizo-
phrenia reported the BP4–BP5 deletion in a total of 16 out of
4123 patients.21 22 In total, a mildly impaired cognitive function
was noted in five of these patients, although other phenotypic
details were not provided. In order to determine whether there
are specific clinical features commonly associated with the
15q13.3 microdeletion, further phenotypic studies in larger
patient groups are necessary. To address this, we carried out
molecular and clinical characterisation of 18 new probands with
a deletion comprising the BP4–BP5 region and one patient with
a BP3–BP4 deletion. In addition, four patients with a duplication
comprising the BP4–BP5 region were included to ascertain the
clinical significance of duplications in this region.
METHODS
Patients and DNA samples
In this study, 19 probands with a submicroscopic deletion and
four patients with submicroscopic duplications in the BP3–BP4–
BP5 region at 15q13.1q13.3 were included. DNA was isolated
according to standard procedures. All patients showed a normal
karyotype at G banded chromosome studies and clinical
information was obtained from the referring physicians.
Except for patients 10 and 15 who were referred for a congenital
cardiac defect solely, all patients were referred because of
development delay, and the 15q13 aberrations were found
during their diagnostic work-up. Apart for patient 1, who was
tested for a CHRNA7 deletion by targeted multiplex ligation
probe amplification (MLPA) analysis in an ongoing study in
epilepsy patients, all the submicroscopic deletions and duplica-
tions of 15q13.1q13.3 were identified with different diagnostic
microarray platforms. The following array platforms were used:
patients 3 and 4—32 k bacterial artificial chromosome (BAC)
array23; patients 5 and 6—1 Mb custom array; patients 2, 7, 8, 9
and 23—44 k Agilent array; patient 10—custom Agilent 105 k
array that included high density oligonucleotide coverage of the
15q13.3 region; patient 11—Signature commercial BAC array;
patients 14 and 15—244 k Agilent array; patients 12 and 17—
HumanCNV370Duo from Illumina; patients 16, 18, 19 and
22—customised 4644 K Agilent oligonucleotide array24;
patients 13, 20 and 21—Affymetrix 250 Nsp single nucleotide
polymorphism (SNP) array. When parents and other family
members were available, de novo or inherited occurrence was
investigated using either fluorescence in situ hybridisation
(FISH), MLPA or microarray analysis.
Molecular testing
The majority of 15q13.1q13.3 rearrangements were fine mapped
using a custom high resolution oligonucleotide array
(NimbleGen Systems Inc, Madison, Wisconsin, USA) consisting
of 135 000 isothermal probes (length 45–75) including 1333
probes within the chromosome 15q13 BP3–BP4–BP5 region
(chr15:25 500 000–31 500 000, hg 18, http://genome.ucsc.edu/).
DNA from patient 1 was analysed using a custom array with
166 000 probes including 42 698 within the same 15q13 interval
(NimbleGen Systems Inc); patient 14 was analysed using a
custom array with 72 000 probes, including 1142 probes within
the same region (NimbleGen Systems Inc). Hybridisations were
performed as described previously25 and a single normal male
control was used as a reference (GM15724, Coriell).
Synthetic MLPA probes were developed in the 15q13.1q15.1
region (27 300 000–38 500 000, hg 18, http://genome.ucsc.edu/)
to test for the BP4–BP5 deletion in the family members of patient
3, 4 and 12 (except for the father of patient 4 who was not
available for testing). The 10 MLPA probes were designed to nine
different genes (NDNL2, TJP1, TRPM1, KLF13, CHRNA7, GREM1
(2x), CHRM5, MEIS2, IVD) in accordance with a protocol
provided by MRC-Holland (www.MRC-holland.com). Probe
hybridisation and analysis was done as previously described by
Schouten et al.26 All reagents for MLPA reaction and subsequent
polymerase chain reaction (PCR) amplification were purchased
from MRC-Holland (MRC-Holland, Amsterdam, The
Netherlands).
RESULTS
Molecular findings
The results of the high resolution targeted 15q13.1q13.3 array
are summarised in fig 1. Sixteen patients (cases 1–16) showed a
BP4–BP5 deletion of which two were proven to be de novo, 11
were inherited (three paternally and eight maternally), and in
three cases the parents were unavailable for testing. These 16
cases were found in a cohort of 6624 persons referred for
idiopathic mental retardation and/or congenital abnormalities
(0.24%). Two patients (cases 17 and 18) had a BP3–BP5 deletion
of which one was proved to be de novo and in the second case
the inheritance was unknown. One patient (case 19) had a
paternally inherited BP3–BP4 deletion. Three patients (cases 20–
22) had a BP4–BP5 duplication of which one was de novo, and in
two patients the parents were unavailable for testing. One patient
(case 23) had a paternally inherited BP3–BP5 duplication.
In several families with a proband with a BP4–BP5 deletion
siblings were tested for this deletion. The deletion was excluded
in the brother of patient 2 (fig 2A). In the family of patient 3 the
deletion was detected in two of the three siblings, and in the
relatives of patient 4 the deletion was found in four out of five
siblings (fig 2B,C and supplemental fig 1). In addition, the BP4–
BP5 deletion was identified in the brother of patient 12 (fig 2D).
In the family of patient 17 the BP3–BP4 deletion was excluded
in a brother of the proband but appeared to be present in her
oldest brother and a paternal uncle (fig 2E).
In addition to the de novo 15q13.3 deletion in patient 13, a
700 kb maternally inherited duplication on 22q11.21q11.22 was
detected. Besides the BP3–BP5 duplication in patient 23, a 200 kb
deletion at 14q31.1 was identified. Both the BP3–BP5 duplication
and the 14q31.1 deletion were also present in her father.
Clinical data
All 23 patients are described in more clinical detail in the section
below. The clinical features of all deletion (n = 19) and
duplication (n = 4) patients are summarised in tables 1 and 2,
respectively. Photographs of patients are shown in those cases
where parents consented for publication.
Deletion cases
Patient 1
This female (fig 3A) was the first child of non-consanguineous
parents and born after an uncomplicated pregnancy with a
Original article
512 J Med Genet 2009;46:511–523. doi:10.1136/jmg.2008.063412
 group.bmj.com on January 28, 2010 - Published by jmg.bmj.comDownloaded from 
weight of 2960 g (25th centile). At the age of 1 month seizures
started. She could walk at the age of 22 months and she
pronounced her first words at 4 years. She showed aggressive
behaviour in infancy. At adult age she was severely mentally
retarded and speech was restricted to few repetitive sentences.
She showed apathetic behaviour, epilepsy and had sleeping
problems. She had a short stature of 147.5 cm (,3rd centile)
and microcephaly with an occipitofrontal circumference (OFC)
Figure 1 High resolution oligonucleotide
array mapping of 15q13–q13.3
rearrangements (chr 15:25.7–31.4 Mb,
Hg 18). Patients 1–16 had a deletion of
BP4–BP5, patients 17–18 a deletion of
BP3–BP5, patient 19 a deletion of BP3–
BP4, patients 20–22 a duplication of
BP4–BP5, and patient 23 a duplication of
BP3–BP5.
Original article
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of 51 cm (,3rd centile). At clinical examination she presented
with an asymmetric skull with bitemporal narrowing, bristly
hair, synophrys, blepharophimosis, squint, a bulbous nasal tip
and folded helices. Furthermore, she had tapering fingers, deep
palmar creases, hypoplastic fourth and fifth toes, an external
rotation of the feet, and multiple pigmented naevi. Magnetic
resonance imaging (MRI) of the brain, at 26 years of age,
showed several abnormalities consisting of an arachnoidal cyst,
parenchymal hypoplasia, subcerebellar picking with dislocation
of parenchymal structures, lateral ventricle dilatation and a mild
corpus callosum hypogenesis. Microarray analysis showed a
BP4–BP5 deletion, which was also present in the normal
mother. Family history revealed a sister in good health and a
second grade cousin of maternal lineage reported with autism.
Patient 2
This boy (fig 3B) was born after a normal pregnancy with a
weight of 4170 g (.99th centile) at 37 weeks of gestation. Early
development was normal apart from a speech delay. At
5.5 years of age he attended a normal school, but with extra
help because of a poor attention span (without hyperactivity)
and difficulties in reading and writing. At that time he was
healthy apart from asthma and he had a normal growth with a
height of 120 cm (91st centile), an OFC of 55 cm (.95th
centile), and a weight of 24.3 kg (50th centile). At physical
examination full eyebrows, S shaped upper eyelids, a fleshy nose
and pigmented naevi were noted. Microarray analysis showed a
BP4–BP5 deletion which was also present in his mother (fig 2A).
She had attended special school during childhood because of
similar reading and writing difficulties as her son. At 35 years of
age she had raised two children and showed normal adaptive
behaviour. She had an OFC of 57 cm (90th centile), coarse hair,
a low frontal hairline, coarse hands and pigmented naevi. Her
other son had similar learning problems to the proband, but did
not have the BP4–BP5 deletion. Evaluation of the family history
revealed a maternal uncle with learning problems.
Patient 3
This girl (fig 3C) was born of non-consanguineous healthy
parents after 42 weeks of pregnancy with a weight of 3500 g
(50th centile). She was treated for a congenital hip dysplasia.
After 4 years of age she developed serious behaviour difficulties
with temper tantrums and sleeping problems with a disrupted
day–night rhythm. At the age of 10 years she had a mild mental
retardation (performance IQ 48, verbal IQ 62, total IQ 53) and
attended special schooling. At 14 years she had a height of
161 cm (20th centile), an OFC of 54 cm (30th centile) and
obvious obesity. She had a hypotonic face, short palpebral
fissures, epicantic folds, a full nasal tip, a small mouth, and
clinodactyly of the fifth fingers.
Microarray analysis showed a BP4–BP5 deletion which was
also present in the healthy father and in two sisters out of three
siblings (fig 2B). The father had finished normal level education.
Remarkably both sisters attended special school for a couple of
years during the initial primary school period. However, they
both continued regular schooling afterwards. They both had a
flat mid-face and short palpebral fissures (like their mother) and
a prominent nasal tip. In addition, the youngest sister had
epicantic folds, clinodactyly of the fifth fingers, and a past
history of impulsive behaviour, anxiety problems and sleeping
difficulties.
Patient 4
This male (fig 3D) was born after 39+3 weeks of gestation with
a weight of 3500 g (20th centile). He showed a severe
psychomotor delay: he could walk at 30 months of age but
never achieved the ability to speak. In his childhood he had
recurrent severe ear infections. An EEG at 14 years of age
Figure 2 Pedigrees of families in which siblings of the proband were
tested. Shaded = mental retardation. Black dot = aberration carrier.
(A) Pedigree patient 2. The mother carried the same BP4–BP5 15q13.3
deletion as identified in the proband, who attends a regular primary
school, with learning problems. The brother also had learning problems
at primary school, but normal chromosomes. (B) Pedigree patient 3. Both
sisters (II-I and II-IV) carried the same BP4–BP5 15q13.3 deletion as
identified in the mild mentally retarded proband and her healthy father.
The deletion was not found in the healthy mother and brother (II-III). Both
sisters had had learning problems for which they attended a period of
special schooling; however, both had continued regular schooling. (C)
Pedigree patient 4. Except for female II-III, all sibs carried the same BP4–
BP5 15q13.3 deletion as identified in the mentally retarded proband and
his healthy mother. Female II-I and male II-V both had had learning
problems in childhood but both showed normal adaptive skills in
adulthood. The remaining siblings (II-II, II-III and II-VI) had never had
learning problems and finished normal primary and secondary school. (D)
Pedigree patient 12. Both brothers had a mild developmental delay and
both carried the BP4–BP5 15q13.3 deletion. The mother was not formally
assessed but she appeared to have a borderline level of intelligence. (E)
Pedigree patient 19. Father and daughter both have a BP3–BP4 deletion.
The same deletion was also identified in her oldest brother and paternal
uncle who had both had normal development. Her mentally retarded
brother was also tested, but did not have the deletion.
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showed no abnormalities. At physical examination at the age of
44 years he was severely mentally retarded, he had a height of
168 cm (,3rd centile), and an OFC of 55 cm (7th centile). He
presented with a high forehead with receding hair, strabismus
convergens, a thin nasal bridge, a pointed nasal tip with the
columella below the alae nasi, a grooved chin, and a mild pectus
excavatum.
Microarray analysis showed a BP4–BP5 deletion. The same
deletion was present in his healthy mother and four of his five
siblings (fig 2C and supplemental fig 1). The mother had
attended normal schooling. Two of the four siblings had had
learning problems in childhood and attended special schooling,
and the other two siblings had visited regular schooling. All
siblings showed normal adaptive skills and two of them had in
total four children of which one had visited special schooling.
Patient 5
This male was born after 40 weeks of gestation with a normal
birth weight of 3425 g (50th centile). Although he was born
with a normal head circumference of 36 cm (50th centile) he
was noted to have developed a macrocephaly with a head
circumference of 54.5 cm (.97th centile) at 5 years 4 months of
age. He could sit at 8 months and walk at 17 months of age. At
the age of 6 years 10 months he showed an apparent speech
delay, had a normal weight and height, macrocephaly, a mild
hypotonia, retinal dystrophy, myopia and several cafe´ au lait
Table 2 Clinical features of all probands with a 15q13 duplication: patients 20–22 (BP4–BP5) and patient 23 (BP3–BP5)
Patient 20 Patient 21 Patient 22 Patient 23
Duplication BP4–BP5 BP4–BP5 BP4–BP5 BP3–BP5
Gender Male Female Female Female
Age 17 yrs 4 yrs, 6 mo 20 yrs 4 yrs, 10 mo
Inheritance NA De novo NA Inherited pat
Mental retardation Mild Mild Mild-moderate Severe
Epilepsy/abnormal EEG 2 2 2 2
Hypotonia + 2 + +
Birth weight P50 .p98 NA P3–P98
Height P30 P50 P3 P25
OFC P60 P45 P60 P50
Current weight NA .P98 NA .P98
Behaviour problems Autistic features,
bipolar disorder
2 Preoccupation with food,
extremely talkative
Autistic features,
self mutilation
Other features
Ocular region Synophrys Hypertelorism Slightly deep set eyes
Nose High nasal bridge
Ears Low set ears,
recurrent ear infections
Low set ears,
recurrent ear infections
Extremities Cut. syndactlyly fingers,
brachydactyly, cut syndactyly 2–3
toes
Single palmar crease
Abdomen/urogenital Cryptorchid testes Inverted nipples
Brain MRI/CT Normal Normal NA normal
CT, computed tomography; EEG, electroencephalogram; mo, months; MRI, magnetic resonance imaging; NA, information not available; OFC, occipitofrontal circumference; pat,
paternal; yrs, years.
Figure 3 Probands with a deletion
comprising BP4–BP5. Photographs of
probands with a deletion of BP4–BP5
from left to right: (A) Patient 1 at
26 years. (B) Patient 2 at 5 years
6 months. (C) Patient 3 at 14 years. (D)
Patient 4 at 40 years. (E) Patient 8 at
1 year 6 months. (F) Patient 9 at 2 years
8 months. (G) Patient 11 at 4 years
9 months. (H) Patient 13 at 11 years. (I)
Patient 16 at 3.5 years of age. In addition,
one patient (J) with a deletion of BP3–
BP5 at 15q13.1q13.3: patient 17 at
17 years. No recognisable facial
phenotype could be established based
upon the facial and further clinical
appearance.
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spots, and no obvious dysmorphisms. MRI of the brain at 1 year
11 months of age showed diffuse changes, and periventricular
and subcortical white matter in the left parietal and temporal
regions. He was not having seizures, behavioural or sleeping
problems. Microarray analysis showed a BP4–BP5 de novo
deletion.
Patient 6
This female proband was born at term with a birth weight of
4050 g (.97th centile). She is a member of a complex socially
disadvantaged family and has two brothers and two sisters.
Another two sisters died in early life, one from sudden death at
5 weeks of age and the other after complications related to
seizures at 2 years of age. The proband attended special primary
school and a career orientated high school during childhood. At
the age of 28 years she functioned at a low normal mental level.
Her stature was 182 cm (98th centile) and she had a weight of
105 kg (.97th centile). Medical history revealed two surgeries
for strabismus and patella luxation, respectively. She never had
seizures or behaviour problems. Microarray analysis showed a
BP4–BP5 deletion which she inherited from her father.
Patient 7
This male was born after 40 weeks of gestation with a normal
weight (80th centile), length (50th centile) and OFC (80th
centile). He could sit at 18 months and walk unsupported at
3 years of age. At the age of 4 years he had an average height
(50th centile) and weight (60th centile) and a large OFC (90th
centile). He showed a severe mental retardation without speech
development, hypotonia and aggressive and impulsive beha-
viour. He did not show apparent dysmorphisms and did not
have seizures. Family history revealed several mild mentally
retarded relatives and two sibs with a severe mental retardation.
Microarray analysis showed a BP4–BP5 deletion which was
inherited from his mother.
Patient 8
This female (fig 3E) was prematurely born after 28 weeks of
gestation with a weight of 1100 g (50th centile), a length of
36 cm (45th centile), and an OFC of 23 cm (3rd centile).
Neonatal cerebral ultrasound was normal. She started to sit
unsupported at 12 months post-term date and showed a delay
in speech development. At 1 year and 6 months she showed a
moderate developmental delay and had a length of 75.5 cm, an
OFC of 44.5 cm (both 10th centile corrected for prematurity)
and a weight of 9290 g (40th centile). She had downslanting
palpebral fissures, ptosis, epicanthic folds, an upward position
of the nares and large low set ears. Family history revealed a
mild mental retardation of the father and two miscarriages.
Microarray analysis showed a BP4–BP5 deletion which was
maternally inherited.
Patient 9
This female (fig 3F) was born after an uncomplicated pregnancy
at 39 weeks 6 days with a weight of 2750 g (,3rd centile) and a
length of 47 cm (,3rd centile). She could walk independently at
2 years of age and had a delayed speech development. At the age
of 2 years 8 months she had a height of 98.5 cm (84th centile), a
weight of 15.6 kg (50th centile) and an OFC of 50 cm (75th
centile). She presented with a mild to moderate mental
retardation and showed autistic behaviour, avoiding eye
contact. An MRI of the brain was normal. She showed no
obvious dysmorphisms except for a clinodactyly of both fifth
fingers and a dry skin. Microarray analysis showed a BP4–BP5
deletion, the inheritance of which remained unknown.
Patient 10
This 9-year-old female presented at birth with a congenital
cardiac defect consisting of a tetralogy of Fallot and a
triphalangeal thumb; the latter was also present in the
father. Birth and current parameters were unavailable. She
showed a normal cognitive development without a history of
mental delay, autism or seizures. She had no apparent
dysmorphisms except for a mild hypertelorism. Microarray
analysis showed a BP4–BP5 deletion, the inheritance of which
remains unknown.
Patient 11
This girl (fig 3G) was born after 40 weeks of pregnancy
complicated by polyhydramnios with a weight of 4400 g
(95th centile). She could sit independently at 9 months and
walk at 19 months of age. Until the age of 3 years she expressed
fewer than five words. At 4 years 9 months of age she showed
developmental delay with fairly poor expressive language and
around 60 words of vocabulary. She did not have seizures and
brain MRI was normal. She has had behaviour problems
consisting of obsessive cleanliness of mouth, face and hands;
she is easily emotionally upset and hypersensitive with crowds
and sounds. Microarray analysis showed a BP4–BP5 deletion
which she inherited from her father. He also had been delayed in
walking and in speech development and attended special school
during childhood. However, at adult age he spoke very well,
could spell and read, and showed normal adaptive behaviour
and raised one child.
Patient 12
This male was born after an uncomplicated pregnancy at
42 weeks of gestation. Speech development was significantly
delayed. At the age of 13 years he was moderately mentally
retarded with an IQ of 49. He had no epilepsy and an MRI of
the brain was normal. Cardiac and ophthalmological examina-
tion were also normal. On a skeletal survey he had a marked
scoliosis and a spina bifida occulta of S1. On clinical examina-
tion he had a nasal speech, a height on the 10th centile, a weight
below the 3rd centile, and a head circumference between the 3rd
and 25th centile. He had a long face, thick eyebrows with a
synophrys, a bulbous nose and large low set ears. The hands
showed bilateral simian creases. Microarray analysis showed a
BP4–BP5 deletion that was also identified in his mother and his
brother (fig 2D). Although his mother was not formally assessed
she appeared to have a borderline level of intelligence. His
brother was mentally retarded with an IQ of 50–56 at the age of
13 years.
Patient 13
This 11-year-old daughter (fig 3H) of non-consanguineous
parents was born at 40 weeks gestation with a weight of
2850 g (3rd centile). At birth bilateral pre-auricular tags were
noted and later surgically removed. She started to walk
unsupported at the age of 2.5 years. An MRI of the brain at
3.5 years of age was normal. At age 5 years she was known to
have a developmental delay of approximately half a year, short
stature (,3rd centile) and absences. At age 7 years her IQ was
estimated to be 50. At that time she visited a regular primary
school, however, with difficulties for which she received extra
help. An EEG at 9 years showed frontal ictal epileptic activity.
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At 11 years she still had a short stature (135.5 cm, ,3rd centile)
and a relative high weight (54 kg, 80th centile), and a normal
OFC. Several dysmorphic features were noted, such as
hypertelorism, blepharophimosis, a full nasal tip, a thin upper
lip, clinodactyly of the fifth fingers, broad hands and feet, and
distal brachydactyly of fingers and toes. Furthermore, she had a
nasal speech and showed normal behaviour. Microarray analysis
revealed a de novo BP4–BP5 deletion.
Patient 14
This 5-year-old male was born at term with a weight of 3150 g
(50th centile) and a length of 49 cm (50th centile). Pregnancy
was complicated with gestational diabetes. Prenatal amniocent-
esis showed a normal 46,XY karyotype. At the age of
18 months, the boy was first evaluated due to developmental
delay, hypotonia and dysmorphic features. On MRI, an
unspecific increased size of the subarachnoideal space was
reported. He never had seizures. Family history was unremark-
able and both parents had normal intelligence as well as his only
sister of 11 years. On examination, he had a height of 102 cm
(3rd centile), a weight of 15 kg (3rd centile), and an OFC of
48 cm (10th centile). He had a long face and long forehead,
downslanting palpebral fissures with lack of eyelashes in the
medial third, arched eyebrows, low set and protruding ears with
overfolded helices, thin upper lip and a large mouth. Sloping
shoulders with protruding scapulae as well as hyperlaxity were
also noticed. He showed friendly behaviour and poor concen-
tration skills. Formal IQ testing had not been performed but at
5 years of age he was functioning at about a 3.5 years level on a
developmental scale for language and motor skills. Microarray
analysis showed a BP4–BP5 deletion, the inheritance of which
remained unknown.
Patient 15
A prenatal diagnosis of cardiac malformation was detected by
fetal ultrasounds at 16 weeks gestation in an otherwise normal
pregnancy and verified 2 weeks later as right cardiac hypoplasia
with severe tricuspid stenosis. Prenatal amniocentesis showed a
normal 46,XX karyotype. Pregnancy was subsequently inter-
rupted due to the bad prognosis of the heart malformation.
The fetal necropsy confirmed the cardiac findings and detected
no other malformations. Both parents were apparently healthy
and with normal intelligence as well as their two living
children, a boy and a girl. The brother of the mother was
reported to have an unspecified cardiac congenital cardiac
defect but he was not available for examination. Microarray
analysis showed a BP4–BP5 deletion that was inherited from
the asymptomatic mother.
Patient 16
This 3.5-year-old girl (fig 3I) was born at 34 weeks of gestation
due to maternal health problems (severe asthma and bronch-
iectasis). After birth she was found to have a pneumothorax.
Family history revealed a mother without educational qualifica-
tions and a father who had learning problems. Furthermore, she
had a brother, who was diagnosed with epilepsy, but had a
normal development. A maternal sister attended special school
during childhood and two of her three children were visiting
special school. At 3.5 years she had a moderate to severe
developmental delay, a poor concentration and behavioural
problems. She had a height of 113.5 cm (91–98th centile), a
weight of 17 kg (75th–90th centile), and an OFC of 51.1 cm
(50th–75th centile), curly blond hair and a large forehead. She
had a broad mouth with a thin upper lip and a protuberant
tongue. She had small widely spaced teeth and a smooth
philtrum. Furthermore, she had faint terminal creases on her
fingers and broad big toes with a wide sandal gap. Microarray
analysis showed a BP4–BP5 deletion that was inherited from the
mother.
Patient 17
This boy (fig 3J) was born with a normal birth weight, length
and OFC. He started to walk at the age of 14 months. His
speech development was delayed and he was diagnosed with a
mild mental retardation for which he received special schooling.
The family history revealed two maternal half brothers, children
of the grandmother, who had had learning difficulties. At the
age of 13 years he presented with signs of pubertas praecox with
a DHEAS (dehydroepiandrosterone sulfate) concentration of
7.55 mmol/l and gynaecomastia. MRI of the brain at 14.5 years
of age showed no abnormalities. An ultrasound of the heart
showed mitral valve prolapse and the size of the left ventricle was
on the upper border of normal. At the age of almost 17 years he
demonstrated profound hyperactive behaviour, enuresis noc-
turna, and apparent speech problems including dyspraxia and
agrammatism. He had a weight of 83 kg (body mass index 30 kg/
m2), a height of 166 cm (between 3rd and 10th centile), and
microcephaly with an OFC of 54 cm (3rd centile). At physical
examination he showed mild hypotonia, obesity, upslanting
palpebral fissures, a synophrys, a short nose with an upturned
nasal tip, a smooth philtrum and several naevi in the neck.
Furthermore, he had a shawl scrotum, scoliosis, clinodactyly of
the fifth fingers and brachydactyly. Microarray analysis showed a
BP3–BP5 deletion which was proven to have occurred de novo.
Patient 18
The pregnancy of this patient was complicated by premature
rupture of membranes at 30 weeks of gestation. This boy was
born at 35 weeks by emergency caesarean section after failure of
induction of labour which had been initiated due to poor fetal
growth. After birth he was treated for minor respiratory
difficulties and mild jaundice. He also had polycythaemia
which resolved spontaneously. His birth weight was 2520 g
(50th centile). At 20 months, he was noted to have develop-
mental delay, hypotonia and dysmorphic features. Family
history revealed a mother with mild to moderate learning
difficulties. He had three siblings with the same parents, one
brother with learning difficulties, and two unaffected siblings.
He also had one half sister with developmental delay and a half
twin sibpair, less than 1 year old, with a possible developmental
delay. The proband was fostered from an early age because his
mother was unable to cope looking after her children. For this
reason information on early development was scarce. At
5.5 years of age his developmental age for gross motor and
speech development was 3.5 years. On examination, at the age
of 8 years, his height was 124.7 cm (25th centile), his weight
was 22.1 kg (9th centile), and he had an OFC of 53 cm (25th
centile). He had long, downslanting palpebral fissures and long
eyelashes, arched eyebrows, large ears and a large mouth. He
had hirsutism on his back, prominent finger pads and broad
finger tips, with short fifth fingers. He was generally hypotonic
in his limbs. He showed friendly behaviour and sometimes had
difficulties in maintaining his concentration. He had not had
any seizures and a cerebral MRI or CT scan had not been
performed. Microarray analysis showed a BP3–BP5 deletion, the
inheritance of which remained unknown.
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Patient 19
This girl was born with a weight of 2250 g (,3rd centile) at
39 weeks of gestation. The pregnancy had been complicated by
intrauterine growth retardation and an elevated a-fetoprotein
(AFP), prompting concern for spina bifida. However, fetal
ultrasound showed a normal anatomy and she presented with a
closed spine at birth. At 9 months she appeared to have a degree
of central hypotonia and failure to thrive. At 2 years of age her
weight had caught up to the 9th centile at 10.7 kg but her
height remained below the 3rd centile. She was microcephalic
with an OFC of 45 cm (,3rd centile). She was functioning at
approximately 16 months for her gross motor skills and other
areas of development. During physical examination hypertelor-
ism, upward slanting palpebral fissures, a prominent nasal root
and brachydactyly were noted. Microarray analysis showed a
BP3–BP4 deletion, which she had inherited from her father who
showed a normal cognitive function. The same deletion was
also confirmed in her 5-year-old brother and paternal uncle,
who had both had a normal development. Her other brother,
aged 4 years, was also mentally retarded but did not have the
BP3–BP4 deletion (fig 2E).
Duplication cases
Patient 20
This male patient was born after 36.5 weeks of gestation with a
weight of 2900 g (50th centile). The family history revealed
psychiatric problems in both parents—the mother had a
personality disorder and recurrent depressions, and the father
was known to have schizophrenia. During childhood he was
fostered for several periods when his mother was hospitalised
for recurrent depression and a borderline personality, therefore
information on early childhood is minimal. CT of the brain and
an EEG at 6 years of age were normal. He had recurrent ear
infections and received a transplant tympanic membrane
because of cholesteatomatosa. At the age of 13 years he was
operated on for a right sided undescended testis. He had a mild
mental retardation and received special education both in
primary and secondary school. He was known to have
aggressive behaviour from childhood onwards. At 17 years he
was diagnosed with a bipolar disorder type II, PDD-NOS
(pervasive development disorder not otherwise specified) and
showed autistic features. At physical examination he presented
with a slender build with small shoulders and narrow thorax,
height of 179.5 cm (30th centile) and an OFC of 58.2 cm (60th
centile). He had a hypotonic narrow face, coarse hair with a
white forelock, synophrys, apparent low set ears with folded
helices and a prominent lobule, a high nasal bridge and wide
spaced teeth. Furthermore, he had short fingers bilaterally with
a mild cutaneous syndactyly of the second, third and fourth
fingers. In addition, he had a partial cutaneous syndactyly of the
second and third toes bilaterally. Microarray analysis revealed a
BP4–BP5 duplication, the occurrence of which could not be
assessed in both parents.
Patient 21
This girl was born with a weight of 4850 g (.98th centile) and a
length of 51 cm (50th centile). At the age of 4 years 6 months
she had a mild developmental delay. At that time she presented
with a stiff way of moving, mild behaviour problems, obesity
and recurrent ear infections. She had a height of 109 cm (50th
centile), an OFC of 50.2 cm (45th centile) and a weight of
26.2 kg (.98th centile). Physical examination revealed mild
dysmorphic facial features consisting of brachycephaly, a broad
and short forehead, low set simple formed ears with flat upper
helices and hypertelorism (the latter also present in mother).
Furthermore she had inverted nipples, a right sided transverse
palmar crease, flat arches of both feet, hypermobility of joints
and dry skin. An MRI of the brain showed no abnormalities.
Microarray analysis revealed a BP4–BP5 duplication which had
occurred de novo.
Patient 22
This female patient had been in foster care since infancy. Early
information was therefore not available and family history was
unknown.
During childhood she attended a special school and had severe
learning difficulties. She did not have major behavioural
problems but was said to have a preoccupation with food and
a tendency to overeat. She was extremely talkative. At 20 years
her height (25th centile) and OFC (60th centile) were normal.
She progressed through puberty normally and had normal
sexual development. On examination she had no apparent
dysmorphisms.
Patient 23
This girl was born after an uneventful pregnancy with a normal
weight, length and OFC. She showed a delayed motor
development and started to walk at 19 months of age. At the
age of 4 years 10 months she had a severe mental retardation
with no obvious motor problems any more. She was overweight
with a weight of 24 kg (.98th centile), and had a normal height
of 105 cm (25th centile) and an OFC of 50 cm (50th centile).
MRI of the brain at the age of 2 years showed no abnormalities.
She had no obvious dysmorphic features although she did not
resemble her parents. She presented with distant behaviour
reminiscent of autism with repetitive rocking and head banging.
In addition to a BP3–BP4 duplication, a 200 kb deletion at
14q31.1 was identified in this girl. Both rearrangements were
also present in her healthy father, who was of normal
intelligence and appearance.
DISCUSSION
To determine the clinical and molecular characteristics of
segmental aneuploidies in the 15q13.3 region, we studied 18
newly identified probands with a deletion comprising the BP4–
BP5 region (including two cases with a deletion of BP3–BP5
region), one patient with a BP3–BP4 deletion only, and four new
probands with a duplication comprising the BP4–BP5 region
(including one case with a duplication of BP3–BP5). The 16 cases
with a BP4–BP5 deletion were found in a cohort of 6624 persons
with idiopathic mental retardation and congenital abnormal-
ities (0.24%).
The deletion cases showed a broad phenotypic variability. Of
the 17 living probands with a BP3–BP5 (n = 2) or BP4–BP5
(n = 15) deletion, 16 had a degree of cognitive impairment
varying from mild learning problems to all levels of mental
retardation. Thirteen relatives carrying the deletion and one
proband (case 10) functioned at a normal cognitive level: the
latter was ascertained for array analysis because of tetralogy of
Fallot and limb abnormalities. In the majority of patients, no
significant dysmorphisms were noted. Behavioural problems
were frequent in our patient cohort (10/17 probands, 59%) and
mainly comprised poor attention span, hyperactivity, and
aggressive and impulsive behaviour (table 1). Another common
feature was hypotonia (8/17 probands, 47%) and a prominent
or bulbous nasal tip (6/17 probands, 35%). Less frequently
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observed features were short stature (4/17 probands, 24%),
strabismus (3/17 probands, 18%), large ears (4/17 probands,
24%), cardiac defects (3/18 probands, 17%), clinodactyly of the
fifth fingers (4/17 probands, 24%), and pigmented naevi (3/17
probands, 18%). However, all these frequencies would be
significantly lower if healthy relatives with the same deletion
were included. In addition, only two patients had a history of
seizures which is less frequent in our cases than those reported
previously,7 and does not support the idea that seizures are a
common manifestation in patients with a 15q13.3 microdele-
tion. Based on the phenotypic features in the individual patients
in this series with a deletion including BP4–BP5, no straightfor-
ward clinically recognisable phenotype could be established
(fig 3, table 1).
We identified one patient (case 18, fig 2E) with a deletion of
BP3–BP4, which was also present in her oldest brother, father
and uncle, who all had normal cognitive development, but was
not present in her mentally retarded brother. A further inherited
BP3–BP4 deletion was previously described in a developmentally
delayed girl and her normal father,7 but not in over 2000
controls in different studies describing copy number variation in
control individuals.27–36 Based upon these numbers, the BP3–BP4
deletion appears to be a rare event which is likely to reflect the
genomic architecture of this region in which there is greater
homology between the inverted repeats at BP4–BP5 than BP3–
BP4. The limited data so far indicate that the BP3–BP4 deletion
is a novel copy number variation of doubtful clinical signifi-
cance, especially as the phenotype of both the BP3–BP5 cases
(case 16 and 17) was not more severely affected than that of
patients with a deletion comprising BP4–BP5 only.
Remarkably, at least 11 of the 16 BP4–BP5 deletions were
inherited. One of these parents had a mild mental retardation
(mother of patient 7), one appeared to have a borderline mental
functioning (mother of patient 12), and four had some learning
difficulties as a child only (parents of patients 2, 3, 11 and 16).
In four different families all siblings were tested, and seven of 10
siblings carried the same deletion (fig 2A–D). One sibling had
mild developmental delay, four had learning problems in
childhood, but functioned normally at a later age, and two
never had learning problems at all. All, but one, parents and
adult siblings showed normal adaptive function and 13 of them
raised children.
In addition, in two recent studies reporting recurrent
microdeletions associated with schizophrenia, a 15q13.3 dele-
tion was identified in seven out of 4123 schizophrenia patients
and eight out of 39 800 controls in the first study,21 and in nine
out of 3391 patients and none of the 3181 controls in the
second.22 The fact that we found the deletion in several normal
family members of mentally retarded probands and in several
controls suggests that the BP4–BP5 deletion alone does not lead
to mental retardation per se.
Therefore, we assume that the BP4–BP5 deletion plays a
significant contributing role in the pathogenesis of different
conditions affecting the brain, such as mental retardation and
schizophrenia, in the affected individuals, but the variable
phenotypic outcome of the deletion is likely to be determined in
conjunction with other factors. This is similar to the 22q11.2
microdeletion syndrome which was initially found in patients
with DiGeorge syndrome and velocardiofacial syndrome pre-
dominantly.37 However, several later studies showed that
individuals, often parents of affected children, with ‘‘subclinical
deletions’’ were more common than previously considered.38–41
The familial occurrence (parent–child) of the 22q11.2 deletion
varied in different studies from 5–28%.37 42–45
Another deletion with a comparable complex inheritance
pattern is the 1q21 microdeletion associated with the thrombo-
cytopenia absent radius (TAR) syndrome.46 47 Although this
deletion was not observed in a normal control population,
approximately 75% of the TAR patients inherited the 1q21
deletion from an unaffected parent. This suggests that
haploinsufficiency of the deleted region alone is not sufficient
to cause TAR syndrome in the carrier parent, but is a
prerequisite for the phenotype in the affected offspring.
Located slightly more distal on chromosome 1q21.1, other
recurrent reciprocal rearrangements have also been described.
These (most commonly 1.35 Mb deletions and duplications)
result in a considerable variability in expressivity among the
probands and in several cases have also been inherited from
apparently unaffected parents.48
A further, recently described, disease susceptibility locus is
16p13.1.49 Deletions of a 1.5 Mb segment on chromosome
16p13.1 are associated with mental retardation, microcephaly,
seizures and behavioural problems. Duplications seem to
predispose to autism in males. However, both aberrations show
incomplete penetrance which is demonstrated by their presence
in apparently unaffected relatives.50
The 15q13.3 microdeletion is associated with a highly variable
intra- and inter-familial clinical phenotype despite the uni-
formity of the chromosome deletion. For the 22q11.2 syndrome
and other microdeletion syndromes various hypotheses have
been proposed to explain the broad phenotypic spectrum also
applicable to the 15q13.3 deletion. Besides the contributing
contiguous genes, one other molecular mechanism might be the
presence of a masked recessive mutation or functional poly-
morphism in one of the genes on the remaining allele, such as
COMT polymorphism described in the 22q11.2 microdeletion
syndrome.51 In the 22q11.2 microdeletion syndrome, the presence
of the low activity variant, in addition to a deletion of the other
allele, is a risk factor for prefrontal cortical volume decline, a lower
cognition and developing psychotic symptoms.51
Epigenetic or environmental factors are another possible
explanation as suggested by discordance in clinical outcome of
monozygotic twins with a 22q11.2 deletion.52 53 The possibility
of expression differences between phenotypically diverse
family members with a 15q13.3 deletion caused by an
imprinting defect, such as in PWS or AS, seems unlikely since
several of the BP4–BP5 deletion cases were inherited from both
males and females as parents of origin (two paternal, five
maternal). Moreover, none of the genes in this region have
been described to possess imprinting characteristics (Genomic
Imprinting Website: www.geneimprint.com/site/genes-by-species,
September 2008).
A further explanation might be that some individuals are able
to overcome one or more impairments, caused by haploinsuffi-
ciency of specific genes, during pre- or postnatal development.
This is consistent with the observation that some individuals
showed a normal development from birth onwards, whereas
others did have some learning problems during childhood, but
functioned at a normal level in adulthood. A similar mechanism
had been proposed for the occurrence of the specific heart
defects in 22q11.2 microdeletion syndrome, where reduction in
penetrance during development was demonstrated in a 22q11.2
deletion mouse model.54 As in humans, not all carrier mice show
a cardiac defect at birth. However, all embryos show abnormal
small fourth pharyngeal arch arteries during early embryogen-
esis in contrast to their wild type counterparts. Many embryos
(68%) later overcome this early defect and develop normally.
This ability to overcome the primary embryological defect
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appears to be a key factor in determining the final penetrance.
We hypothesise a similar mechanism could play a role for
cognitive functioning in 15q13.3 cases.
In addition, we described four patients with a duplication on
15q13.1q13.3: three cases with a duplication of the BP4–BP5
region and one patient with a BP3–BP5 duplication. Features
noted in at least two out of four affected individuals in addition
to the mental retardation were behavioural problems, autism,
hypotonia, obesity, recurrent ear infections and low set ears.
None of these patients had structural brain abnormalities or
epileptic seizures. Although some dysmorphic features were
noted in individual patients, these patients did not share a
common recognisable phenotype (table 2).
To conclude whether this duplication is pathogenic is rather
difficult with the limited number of patients (n = 4) in our
cohort and the unknown inheritance of the duplication in two
of them. Remarkably, the duplication was proven de novo in
one of the patients, which could be interpreted as evidence of
pathogenicity, but it was inherited from a normal parent in one
of the other patients and two duplications in the BP3–BP4–BP5
region have been identified in a control set consisting of 960
non-retarded individuals.7 The duplication might be a genetic
modifier contributing to mental retardation and future studies
of persons with 15q13 duplications are needed to determine
whether there is a correlation with psychiatric disease and
cognitive functioning in these patients.
There are six known genes (fig 1) within the BP4–BP5 region
(29.0–30.5 Mb, hg 18), any or all of which may contribute to
the phenotypes observed in patients with deletions. The
CHRNA7 gene encodes a synaptic ion channel protein mediat-
ing neuronal signal transmission. It has been suggested that the
CHRNA7 gene is an interesting candidate gene in the
pathogenesis of epilepsy,55 56 but the frequency of epilepsy in
our cohort probands was relatively low (12%). If all BP4–BP5
carriers (probands and relatives) are considered, the frequency
becomes even lower (6%). Interestingly, several patients with a
deletion showed apparent behavioural problems such as
aggressive and impulsive behaviour, autism, short attention
span and hyperactivity. Moreover, in two patients with a
duplication, clear psychiatric disease was reported: one patient
presented with autistic features and bipolar disorder and
another patient showed autistic behaviour and self mutilation.
Interestingly, patients with supernumerary marker(15) chromo-
somes frequently show autistic behaviour. Although these
duplications are often confined to the PWS/AS region (BP1–
BP3), patients with larger markers including BP4 and BP5 have
been described.57–59 Different studies have shown linkage of
markers in the proximity of the CHRNA7 gene with schizo-
phrenia, with an endophenotype of schizophrenia (the P50
sensory gating disorder) and with bipolar disorder.60–62 However,
these findings were not consistently replicated.63 64 Recently
BP4–BP5 deletions have been described in 16 individuals with
schizophrenia, one of whom also had autism.21–22 This associa-
tion with psychiatric disease suggests an even broader develop-
mental impact of the BP4–BP5 deletion than previously
recognised. Remarkably, none of our deletion carriers, probands
and relatives had schizophrenia, although one patient had
autism and several cases showed apparent behaviour problems.
Neither of the two schizophrenia studies discusses whether
duplications of the same region have been found in these
individuals. In our series, one duplication case with bipolar
disorder, a disease closely related to schizophrenia, had a father
with schizophrenia who was unfortunately unavailable for
testing. In order to establish a possible relationship of
duplications in this region with psychiatric disorders further
studies will be necessary.
Cardiac defects were noted in three deletion patients (18%):
one patient with mitral valve prolapse and a slightly enlarged
left ventricle, one patient with tetralogy of Fallot, and a fetal
case with right cardiac hypoplasia with severe tricuspid stenosis.
Interestingly, one of the genes within the BP4–BP5 region is
KLF13 (Kruppel-like transcription factor 13) encoding a member
of the Kruppel-like family of zinc finger proteins that was
recently identified as a regulator of cardiac gene expression and
heart morphogenesis.65 KLF13 is a well conserved gene and a
functional knockdown of KLF13 in Xenopus embryos results in a
cardiac phenotype. In these embryos initial heart development
was normal but, 5 days post-fertilisation, the heart was visibly
smaller and histological examination of the KLF13 depleted
hearts showed several defects including a lack of ventricular
trabeculation, atrial septal defects, delayed atrioventricular
cushion formation and maturation of valves.66 We suggest that
the finding of a 15q13.3 deletion, comprising the KLF13 gene, in
a patient should warrant further cardiac evaluation.
In conclusion, the clinical significance of the 15q13.3
microduplication remains uncertain, although it may be
associated with cognitive impairment and psychiatric disease.
The 15q13.3 microdeletion does not lead to an as yet clinically
recognisable syndrome but comprises an extensive clinical
spectrum ranging from normal development to learning
problems, to mild and even severe mental retardation, and
may also predispose to psychiatric disease. The existence of
microdeletions, associated with an unpredictable and variable
phenotypic outcome, will present the clinician with diagnostic
difficulties and will challenge us to re-evaluate the commonly
used paradigm in the diagnostic setting—that aberrations
inherited from a phenotypically normal parent are usually
non-pathogenic.
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